Paracrine-endocrine FGF chimeras as potent therapeutics for metabolic diseases

BACKGROUND: The development of a clinically useful fibroblast growth factor 21 (FGF21) hormone has been impeded by its inherent instability and weak FGF receptor (FGFR) binding affinity. There is an urgent need for innovative approaches to overcome these limitations. METHODS: We devised a structure-...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:EBioMedicine
Hlavní autoři: Zhao, Longwei, Niu, Jianlou, Lin, Huan, Zhao, Jing, Liu, Yang, Song, Zihui, Xiang, Congshang, Wang, Xiaojie, Yang, Yong, Li, Xiaokun, Mohammadi, Moosa, Huang, Zhifeng
Médium: Artigo
Jazyk:Inglês
Vydáno: Elsevier 2019
Témata:
Research paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6838362/
https://ncbi.nlm.nih.gov/pubmed/31631034
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ebiom.2019.09.052
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky